I am a healthcare professional


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.

Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.

By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.

You can find out more about cookies by browsing our Privacy Policy.


For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Roche and Genentech at

ESMO BC 2024

Coming soon
03:09 PM
Duration 70mins Berlin Hall
Interim analysis (IA) of the atezolizumab (atezo) + sacituzumab govitecan (SG) arm in patients (pts) with triple-negative breast cancer (TNBC) in MORPHEUS pan BC: A Phase Ib/II study of multiple treatment (tx) combinations in pts with locally advanced/metastatic BC (LA/mBC)
Schmid P, Loi S, De la Cruz L, Yerushalmi R, Im SA, Sonnenblick A, Martinez M, Moreno I, Kennedy L, Griffiths K, Schwab R, Young F, Liao L, Dupree K, Kim SB

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
02:57 PM
Duration 70mins Berlin Hall
IMpassion132 double-blind randomised phase 3 trial of chemotherapy ± atezolizumab for early-relapsing unresectable locally advanced or metastatic triple-negative breast cancer
R. Dent, F. André, A. Gonçalves, M. Martin, P. Schmid, F. Schütz, S. Kummel, S.M. Swain, A. Bilici, D. Loirat, R. Villalobos Valencia, S.-A. Im, Y.H. Park, Z.K. Machackova, J. Mouta, R.J. Deurloo, X. Gan, M. Fan, A. Swat and J. Cortés

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
10:00 AM
Duration 60mins Berlin, Germany
Atezolimab (A) + pertuzumab + trastuzumab (PH) + chemotherapy (CT) in HER2-positive early breast cancer (HER2+ eBC): Final results of the phase III IMpassion050 trial
Huober J, Barrios CH, Niikura N, Jarzab M, Chang YC, SL Huggins-Puhalla, Pedrini J, Zhukova L, Curran M, Eiger D, Craine V, Lambertini C, Restuccia E, Zhang H

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 60mins Berlin, Germany
Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) plus chemotherapy in HER2-positive early breast cancer (EBC): Long-term efficacy and safety analysis of the randomised, open-label, multicentre Phase III (neo)adjuvant FeDeriCa study
Jackisch C, Im S-A, Mattar A, Colomer R, Stroyakovskii D, Nowecki Z, De Laurentiis M, Pierga J-Y, Jung KH, Schem C, Heeson S, Crane V, Wang B, Restuccia E, Tan A

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar